Biotech Venture Capital Investors Face Major Disruption After Decades of Success

For decades, venture capital investors have used a simple playbook to make money in biotech. They would invest at specific moments during drug development - like after animal testing but before human trials, or after early human trial results came in.

This timing allowed investors to spot valuable opportunities before others and reduce their risk. VCs could see some proof that a drug might work before putting in their money.

Now that approach is being disrupted. Young biotech companies are struggling to raise money, especially for Series B funding rounds that typically happen after initial development. This period is often called the 'valley of death' because so many companies fail to secure the cash they need.

The funding crunch is forcing biotech startups to change how they operate. Many need money before they have strong data showing their drugs work, making it harder to attract traditional VC investment.

Meanwhile, big pharmaceutical companies are stepping in earlier. They want new innovations and are moving more aggressively to get involved at the beginning of a company's life cycle.